Clinical Trial Update: Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD [Phase 3]

View source ↗

Summary

This Phase 3 study evaluates the 18F-XTR006 PET imaging tracer across cognitively normal subjects, individuals with mild cognitive impairment, and Alzheimer's d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• 18F-XTR006 (XTR006)

Snippet

Sponsor: Sinotau Pharmaceutical Group | Conditions: Alzheimer Disease, Neurofibrillary Tangle | Phase 3 | Status: RECRUITING